The FDA approved Ilumya for adults with active psoriatic arthritis, adding a clinic-administered IL-23 inhibitor option as detailed results from pivotal trials remain unpublished.
Ilumya Wins FDA Approval for Psoriatic Arthritis, Adding a Provider-Given IL-23 Option for Adults With Joint Pain
by | Nov 1, 2026 | Uncategorized | 0 comments
Recent Comments